Literature DB >> 25079688

Tumoral RANKL activates astrocytes that promote glioma cell invasion through cytokine signaling.

Jun-Kyum Kim1, Xiong Jin1, Young-Woo Sohn2, Xun Jin3, Hee-Young Jeon1, Eun-Jung Kim1, Seok Won Ham2, Hye-Min Jeon1, So-Young Chang2, Se-Yeong Oh3, Jinlong Yin4, Sung-Hak Kim5, Jong Bae Park4, Ichiro Nakano6, Hyunggee Kim7.   

Abstract

The invasiveness of glioblastoma is a major cause of poor prognosis and relapse. However, the molecular mechanism controlling glioma cell invasion is poorly understood. Here, we report that receptor activator of nuclear factor kappa-B (NFκB) ligand (RANKL) promotes glioma cell invasion in vivo, but not in vitro. Unlike the invasiveness under in vitro culture conditions, in vivo xenograft studies revealed that LN229 cells expressing high endogenous RANKL generated more invasive tumors than U87MG cells expressing relatively low endogenous RANKL. Consistently, RANKL-overexpressing U87MG resulted in invasive tumors, whereas RANKL-depleted LN229 generated rarely invasive tumors. We found that the number of activated astrocytes was markedly increased in the periphery of RANKL-high invasive tumors. RANKL activated astrocytes through NFκB signaling and these astrocytes in turn secreted various factors which regulate glioma cell invasion. Among them, transforming growth factor β (TGF-β) signaling was markedly increased in glioblastoma specimens and xenograft tumors expressing high levels of RANKL. These results indicate that RANKL contributes to glioma invasion by modulating the peripheral microenvironment of the tumor, and that targeting RANKL signaling has important implications for the prevention of highly invasive glioblastoma.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Astrocyte; Glioblastoma; RANKL signaling; Tumor-invasive microenvironment

Mesh:

Substances:

Year:  2014        PMID: 25079688     DOI: 10.1016/j.canlet.2014.07.034

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  30 in total

Review 1.  Reactive Astrocytes in Glioblastoma Multiforme.

Authors:  Xiudong Guan; Md Nabiul Hasan; Shelly Maniar; Wang Jia; Dandan Sun
Journal:  Mol Neurobiol       Date:  2018-01-23       Impact factor: 5.590

2.  Aquaporin-4 Gene Polymorphisms in Relapsing Inflammatory Optic Neuropathy and RANKL in Glioblastoma: Research and Progress on Biomarkers.

Authors:  Elif Şanli; Erdem Tüzün
Journal:  Noro Psikiyatr Ars       Date:  2021-05-27       Impact factor: 1.339

Review 3.  Intratumoral heterogeneity in glioblastoma: don't forget the peritumoral brain zone.

Authors:  Jean-Michel Lemée; Anne Clavreul; Philippe Menei
Journal:  Neuro Oncol       Date:  2015-07-22       Impact factor: 12.300

4.  LIM domain only 2 induces glioma invasion via cytosolic p27(KIP1).

Authors:  Cheol Gyu Park; Young-Woo Sohn; Eun-Jung Kim; Sung-Hak Kim; Sung-Chan Kim; Hyunggee Kim
Journal:  Tumour Biol       Date:  2015-09-18

5.  Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization.

Authors:  Delphine Garnier; Brian Meehan; Thomas Kislinger; Paul Daniel; Ankit Sinha; Bassam Abdulkarim; Ichiro Nakano; Janusz Rak
Journal:  Neuro Oncol       Date:  2018-01-22       Impact factor: 12.300

Review 6.  Glioma Cell and Astrocyte Co-cultures As a Model to Study Tumor-Tissue Interactions: A Review of Methods.

Authors:  Ivan V Chekhonin; Dimitry A Chistiakov; Nadezhda F Grinenko; Olga I Gurina
Journal:  Cell Mol Neurobiol       Date:  2018-05-10       Impact factor: 5.046

Review 7.  Extracellular Vesicle-Mediated Bilateral Communication between Glioblastoma and Astrocytes.

Authors:  Lisa Nieland; Liza M Morsett; Marike L D Broekman; Xandra O Breakefield; Erik R Abels
Journal:  Trends Neurosci       Date:  2020-11-21       Impact factor: 13.837

Review 8.  Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments.

Authors:  Mahmoud S Alghamri; Brandon L McClellan; Carson S Hartlage; Santiago Haase; Syed Mohd Faisal; Rohit Thalla; Ali Dabaja; Kaushik Banerjee; Stephen V Carney; Anzar A Mujeeb; Michael R Olin; James J Moon; Anna Schwendeman; Pedro R Lowenstein; Maria G Castro
Journal:  Front Pharmacol       Date:  2021-05-18       Impact factor: 5.988

9.  Reduced Serum sRANKL and sTREM2 Levels in High-Grade Gliomas: Association with Prognosis.

Authors:  Mustafa Efendioğlu; Elif Şanli; Ceren Türkoğlu; Naci Balak
Journal:  Noro Psikiyatr Ars       Date:  2021-06-03       Impact factor: 1.339

Review 10.  Targeting Glioblastoma Tumor Microenvironment.

Authors:  Megan Butler; Sahdeo Prasad; Sanjay K Srivastava
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.